| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Y Suzuki, N Tsuneyama, N Fukui, T Sugai, J Watanabe, S Ono, M Saito, Y Inoue, T Somey. Effect of risperidone metabolism and P-glycoprotein gene polymorphism on QT interval in patients with schizophrenia. The pharmacogenomics journal. vol 14. issue 5. 2015-10-12. PMID:24589909. |
effect of risperidone metabolism and p-glycoprotein gene polymorphism on qt interval in patients with schizophrenia. |
2015-10-12 |
2023-08-12 |
human |
| Hiroyoshi Takeuchi, Takefumi Suzuki, Gary Remington, Koichiro Watanabe, Masaru Mimura, Hiroyuki Uchid. Lack of effect of risperidone or olanzapine dose reduction on metabolic parameters, prolactin, and corrected QT interval in stable patients with schizophrenia. Journal of clinical psychopharmacology. vol 34. issue 4. 2015-09-28. PMID:24911439. |
lack of effect of risperidone or olanzapine dose reduction on metabolic parameters, prolactin, and corrected qt interval in stable patients with schizophrenia. |
2015-09-28 |
2023-08-13 |
Not clear |
| Denis Rybin, Gheorghe Doros, Robert Rosenheck, Robert Le. The impact of missing data on the results of a schizophrenia study. Pharmaceutical statistics. vol 14. issue 1. 2015-09-28. PMID:25327503. |
data were obtained from a randomized clinical trial involving 369 patients diagnosed with schizophrenia that compared long-acting injectable risperidone with a psychiatrist's choice of oral treatment. |
2015-09-28 |
2023-08-13 |
Not clear |
| Ahmad Ghanizadeh, Sara Dehbozorgi, Motahhar OmraniSigaroodi, Zahra Rezae. Minocycline as add-on treatment decreases the negative symptoms of schizophrenia; a randomized placebo-controlled clinical trial. Recent patents on inflammation & allergy drug discovery. vol 8. issue 3. 2015-09-14. PMID:25353174. |
forty three patients with schizophrenia diagnosed according to dsm-iv were randomly allocated into minocycline (200mg/d) + risperidone group (n = 21) or placebo + risperidone group (n = 22). |
2015-09-14 |
2023-08-13 |
Not clear |
| Ahmad Ghanizadeh, Sara Dehbozorgi, Motahhar OmraniSigaroodi, Zahra Rezae. Minocycline as add-on treatment decreases the negative symptoms of schizophrenia; a randomized placebo-controlled clinical trial. Recent patents on inflammation & allergy drug discovery. vol 8. issue 3. 2015-09-14. PMID:25353174. |
this trial supports the effectiveness of minocycline as an adjuvant treatment with risperidone for treating negative symptoms of patients with schizophrenia. |
2015-09-14 |
2023-08-13 |
Not clear |
| Somaia Mohamed, Robert A Rosenheck, Haiqun Lin, Marvin Swartz, Joseph McEvoy, Scott Strou. Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia. The Journal of nervous and mental disease. vol 203. issue 7. 2015-09-10. PMID:26075840. |
the clinical antipsychotic trial of intervention effectiveness study randomly assigned 1432 patients formally diagnosed with schizophrenia to four second-generation antipsychotic drugs (olanzapine, risperidone quetiapine, and ziprasidone) and one first-generation antipsychotic (perphenazine) and followed them for up to 18 months. |
2015-09-10 |
2023-08-13 |
Not clear |
| Celine M Laffont, Roberto Gomeni, Bo Zheng, Christian Heidbreder, Paul J Fudala, Azmi F Nasse. Population pharmacokinetic modeling and simulation to guide dose selection for RBP-7000, a new sustained-release formulation of risperidone. Journal of clinical pharmacology. vol 55. issue 1. 2015-08-31. PMID:25043337. |
rbp-7000 is a long-acting formulation of risperidone designed for once-monthly subcutaneous injection for the treatment of schizophrenia. |
2015-08-31 |
2023-08-13 |
Not clear |
| Yutaka Mizuki, Manabu Takak. Blonanserin ameliorated the tendency toward QTc prolongation associated with risperidone in a patient with schizophrenia. Journal of clinical psychopharmacology. vol 35. issue 1. 2015-08-28. PMID:25502488. |
blonanserin ameliorated the tendency toward qtc prolongation associated with risperidone in a patient with schizophrenia. |
2015-08-28 |
2023-08-13 |
Not clear |
| Laura Alexandra Nussbaum, Victor Dumitraşcu, Anca Tudor, Raluca Grădinaru, Nicoleta Andreescu, Maria Pui. Molecular study of weight gain related to atypical antipsychotics: clinical implications of the CYP2D6 genotype. Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie. vol 55. issue 3. 2015-08-25. PMID:25329115. |
our study, performed in 2009-2014, with a two-year enrolment period during which we recruited children and adolescents with a diagnosis of schizophrenia or bipolar disorder on treatment with the antipsychotics (risperidone, aripiprazole or olanzapine), included 81 patients, aged between 9 and 20 years, median age being 15.74 years. |
2015-08-25 |
2023-08-13 |
Not clear |
| Alan M Laties, Allan J Flach, Irina Baldycheva, Ihor Rak, Willie Earley, Sanjeev Patha. Cataractogenic potential of quetiapine versus risperidone in the long-term treatment of patients with schizophrenia or schizoaffective disorder: a randomized, open-label, ophthalmologist-masked, flexible-dose, non-inferiority trial. Journal of psychopharmacology (Oxford, England). vol 29. issue 1. 2015-08-21. PMID:25315830. |
cataractogenic potential of quetiapine versus risperidone in the long-term treatment of patients with schizophrenia or schizoaffective disorder: a randomized, open-label, ophthalmologist-masked, flexible-dose, non-inferiority trial. |
2015-08-21 |
2023-08-13 |
Not clear |
| Alan M Laties, Allan J Flach, Irina Baldycheva, Ihor Rak, Willie Earley, Sanjeev Patha. Cataractogenic potential of quetiapine versus risperidone in the long-term treatment of patients with schizophrenia or schizoaffective disorder: a randomized, open-label, ophthalmologist-masked, flexible-dose, non-inferiority trial. Journal of psychopharmacology (Oxford, England). vol 29. issue 1. 2015-08-21. PMID:25315830. |
quetiapine was non-inferior to risperidone for changes in lens opacity grade in patients with schizophrenia or schizoaffective disorder, indicating that quetiapine does not have clinically significant cataractogenic potential during long-term treatment. |
2015-08-21 |
2023-08-13 |
Not clear |
| Siegfried Kasper, Gino Montagnani, Graziella Trespi, Mario Di Fiorin. Treatment of depressive symptoms in patients with schizophrenia: a randomized, open-label, parallel-group, flexible-dose subgroup analysis of patients treated with extended-release quetiapine fumarate or risperidone. International clinical psychopharmacology. vol 30. issue 1. 2015-08-04. PMID:25356632. |
treatment of depressive symptoms in patients with schizophrenia: a randomized, open-label, parallel-group, flexible-dose subgroup analysis of patients treated with extended-release quetiapine fumarate or risperidone. |
2015-08-04 |
2023-08-13 |
Not clear |
| Siegfried Kasper, Gino Montagnani, Graziella Trespi, Mario Di Fiorin. Treatment of depressive symptoms in patients with schizophrenia: a randomized, open-label, parallel-group, flexible-dose subgroup analysis of patients treated with extended-release quetiapine fumarate or risperidone. International clinical psychopharmacology. vol 30. issue 1. 2015-08-04. PMID:25356632. |
the present analysis assessed the efficacy of extended-release quetiapine fumarate (quetiapine xr) versus risperidone in patients with schizophrenia and depressive symptoms [hamilton depression rating scale (ham-d) score≥20 and a ham-d item 1 score≥2]. |
2015-08-04 |
2023-08-13 |
Not clear |
| Siegfried Kasper, Gino Montagnani, Graziella Trespi, Mario Di Fiorin. Treatment of depressive symptoms in patients with schizophrenia: a randomized, open-label, parallel-group, flexible-dose subgroup analysis of patients treated with extended-release quetiapine fumarate or risperidone. International clinical psychopharmacology. vol 30. issue 1. 2015-08-04. PMID:25356632. |
change in calgary depression scale for schizophrenia score was greater for quetiapine xr than for risperidone [least squares means: -7.2 vs. -4.8; treatment difference 2.4 (95% confidence interval 0.3-4.6; p<0.05)]. |
2015-08-04 |
2023-08-13 |
Not clear |
| Siegfried Kasper, Gino Montagnani, Graziella Trespi, Mario Di Fiorin. Treatment of depressive symptoms in patients with schizophrenia: a randomized, open-label, parallel-group, flexible-dose subgroup analysis of patients treated with extended-release quetiapine fumarate or risperidone. International clinical psychopharmacology. vol 30. issue 1. 2015-08-04. PMID:25356632. |
quetiapine xr was superior to risperidone at reducing depressive symptoms in patients with schizophrenia. |
2015-08-04 |
2023-08-13 |
Not clear |
| David Bin-Chia Wu, Edwin Ho Ming Lee, Wai Sau Chung, Danielle Pui Yu Chow, Vivian Wing Yan Lee, Ming Cheuk Wong, Kenneth Kwing Chin Le. Cost analysis of risperidone long-acting injection in the treatment of schizophrenia and schizoaffective disorders in Hong Kong: an approach using generalised estimating equations. Psychiatry research. vol 210. issue 3. 2015-08-03. PMID:24012164. |
cost analysis of risperidone long-acting injection in the treatment of schizophrenia and schizoaffective disorders in hong kong: an approach using generalised estimating equations. |
2015-08-03 |
2023-08-12 |
Not clear |
| Atefeh Zeinoddini, Morvarid Ahadi, Mehdi Farokhnia, Farzin Rezaei, Mina Tabrizi, Shahin Akhondzade. L-lysine as an adjunct to risperidone in patients with chronic schizophrenia: a double-blind, placebo-controlled, randomized trial. Journal of psychiatric research. vol 59. 2015-07-28. PMID:25227564. |
l-lysine as an adjunct to risperidone in patients with chronic schizophrenia: a double-blind, placebo-controlled, randomized trial. |
2015-07-28 |
2023-08-13 |
Not clear |
| Atefeh Zeinoddini, Morvarid Ahadi, Mehdi Farokhnia, Farzin Rezaei, Mina Tabrizi, Shahin Akhondzade. L-lysine as an adjunct to risperidone in patients with chronic schizophrenia: a double-blind, placebo-controlled, randomized trial. Journal of psychiatric research. vol 59. 2015-07-28. PMID:25227564. |
the objective of this study was to investigate the efficacy and safety of l-lysine as an adjunctive to risperidone in the treatment of patients with chronic schizophrenia during an 8-week trial. |
2015-07-28 |
2023-08-13 |
Not clear |
| Atefeh Zeinoddini, Morvarid Ahadi, Mehdi Farokhnia, Farzin Rezaei, Mina Tabrizi, Shahin Akhondzade. L-lysine as an adjunct to risperidone in patients with chronic schizophrenia: a double-blind, placebo-controlled, randomized trial. Journal of psychiatric research. vol 59. 2015-07-28. PMID:25227564. |
seventy-two chronic schizophrenia inpatients with a positive and negative syndrome scale (panss) total score of ≥ 60 participated in a randomized, double-blind, placebo-controlled trial in the active phase of their disease and underwent 8 weeks of treatment with either l-lysine (6 g/day) or placebo as an adjunctive to risperidone. |
2015-07-28 |
2023-08-13 |
Not clear |
| Stoyo Karamihalev, Jos Prickaerts, Nick P van Goethe. Donepezil and the alpha-7 agonist PHA 568487, but not risperidone, ameliorate spatial memory deficits in a subchronic MK-801 mouse model of cognitive impairment in schizophrenia. Behavioural brain research. vol 272. 2015-07-16. PMID:25036424. |
donepezil and the alpha-7 agonist pha 568487, but not risperidone, ameliorate spatial memory deficits in a subchronic mk-801 mouse model of cognitive impairment in schizophrenia. |
2015-07-16 |
2023-08-13 |
mouse |